RPC4046, a Novel Anti-Interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 Α1 and Α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-In-Human Study
Advances in Therapy- United States
doi 10.1007/s12325-017-0525-8
Full Text
Abstract
Available in
Date
April 28, 2017
Authors
Publisher
Springer Science and Business Media LLC